Risk factors

Cytokinetics (CYTK) risk factors

Item 1A of every Cytokinetics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open CYTK in Gloom →
Cytokinetics' chart, financials and news, free in your browser.Open CYTK in Gloom →
  • FY2025 10-K risk factors
    29 risks7 new11 dropped11 reworded

    MYQORZO’s December 2025 approval shifts risk toward commercialization, including market acceptance, REMS compliance, manufacturing and profitability.

    Filed Feb 26, 2026
  • FY2024 10-K risk factors
    33 risks

    Clinical and regulatory failure could prevent approval of aficamten and other drug candidates.

    Filed Feb 27, 2025